Investigating the effects of long-term dornase alfa use on lung function using registry data
Dornase alfa (DNase) is one of the commonest cystic fibrosis (CF) treatments and is often used for many years. However, studies have not evaluated the effectiveness of its long-term use. We aimed to use UK CF Registry data to investigate the effects of one-, two-, three-, four- and five-years of DNase use on lung function to see if the benefits of short-term treatment use are sustained long term. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - August 29, 2018 Category: Respiratory Medicine Authors: S.J. Newsome, R.M. Daniel, S.B. Carr, D. Bilton, R.H. Keogh Tags: Original Article Source Type: research
Dornase Alfa Ototoxic Effects in Animals and Efficacy for Clogged Tympanostomy Tubes in Children
This pilot study investigates the ototoxic effects of dornase alfa in a chinchilla model and its efficacy vs ofloxacin in a randomized clinical trial of children with clogged tympanostomy tubes. (Source: JAMA Otolaryngology - Head and Neck Surgery)
Source: JAMA Otolaryngology - Head and Neck Surgery - August 2, 2018 Category: ENT & OMF Source Type: research
P029 Upper airway symptoms in CF - is dornase alfa administered by pulsating aerosol a treatment option?
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - June 1, 2018 Category: Respiratory Medicine Authors: F. Haynes, R. Ledermueller, H. Mentzel Tags: Poster Sessions Source Type: research
Outcome evaluation of a pharmacy ‐based therapy management program for patients with cystic fibrosis
ConclusionA pharmacy‐based therapy management program for CF patients was associated with higher adherence to inhaled tobramycin and lower ER rates. Pharmacies that provide therapy management can support effective CF care management. (Source: Pediatric Pulmonology)
Source: Pediatric Pulmonology - March 1, 2018 Category: Respiratory Medicine Authors: Heather S. Kirkham, Francis Staskon, Nishita Hira, Darren McLane, Karl M. Kilgore, Alexis Parente, Seung Kim, Gregory S. Sawicki Tags: ORIGINAL ARTICLE: CYSTIC FIBROSIS Source Type: research
Endonuclease from Gram-Negative Bacteria Serratia marcescens Is as Effective as Pulmozyme in the Hydrolysis of DNA in Sputum
Gulnaz Vafina, Elmira Zainutdinova, Emil Bulatov, Maria N. Filimonova (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - February 16, 2018 Category: Drugs & Pharmacology Source Type: research
Inhaled mannitol for cystic fibrosis.
CONCLUSIONS: There is moderate-quality evidence to show that treatment with mannitol over a six-month period is associated with an improvement in some measures of lung function in people with cystic fibrosis compared to control. There is low to very low-quality evidence suggesting no difference in quality of life for participants taking mannitol compared to control. This review provides very low-quality evidence suggesting no difference in lung function or quality of life comparing mannitol to dornase alfa alone and to mannitol plus dornase alfa.The clinical implications from this review suggest that mannitol could be cons...
Source: Cochrane Database of Systematic Reviews - February 9, 2018 Category: General Medicine Authors: Nevitt SJ, Thornton J, Murray CS, Dwyer T Tags: Cochrane Database Syst Rev Source Type: research
Health Insurance and Use of Recommended Routine Care in Adults with Cystic Fibrosis.
CONCLUSIONS: For adults with CF in the US, public insurance was associated with greater use of routine care than private coverage. Being uninsured was strongly associated with not using routine care. Further efforts to improve access to CF care should address the feasibility of universal and continuous insurance coverage in the CF population. This article is protected by copyright. All rights reserved.
PMID: 29356436 [PubMed - as supplied by publisher] (Source: Respiratory Care)
Source: Respiratory Care - January 22, 2018 Category: Respiratory Medicine Authors: Li SS, Hayes D, Tobias JD, Morgan WJ, Tumin D Tags: Clin Respir J Source Type: research
Health Insurance and Use of Recommended Routine Care in Adults with Cystic Fibrosis
Conclusions. For adults with CF in the US, public insurance was associated with greater use of routine care than private coverage. Being uninsured was strongly associated with not using routine care. Further efforts to improve access to CF care should address the feasibility of universal and continuous insurance coverage in the CF population. This article is protected by copyright. All rights reserved. (Source: The Clinical Respiratory Journal)
Source: The Clinical Respiratory Journal - January 22, 2018 Category: Respiratory Medicine Authors: Susan S. Li, Don Hayes, Joseph D. Tobias, Wayne J. Morgan, Dmitry Tumin Tags: Original Article Source Type: research
Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review
International Forum of Allergy&Rhinology, EarlyView. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - January 11, 2018 Category: Allergy & Immunology Authors: Gopi B.ShahMD, MPH
,
LindeDe KeyzerMD
,
Joy A.RussellPhD, MLS
,
AshleighHaldermanMD Source Type: research
Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review
ConclusionTopical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - January 11, 2018 Category: Allergy & Immunology Authors: Gopi B. Shah, Linde Keyzer, Joy A. Russell, Ashleigh Halderman Tags: ORIGINAL ARTICLE Source Type: research
Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change
ConclusionsWe have studied populations of patients with CF receiving dornase alfa who were switched between regimens to characterize clinical course. Our results suggest that the most common clinical attribute associated with switching from QD to BID dornase alfa was a marked deterioration in stability characterized by increased incidence and frequency of pulmonary exacerbation. For this population, deterioration in lung function did not appear to be a driver for this switch. In contrast, patients receiving BID dornase alfa who were ultimately switched to QD appeared to be clinically stable, on average, suggesting that tre...
Source: Pediatric Pulmonology - October 24, 2017 Category: Respiratory Medicine Authors: Donald R. VanDevanter, Marcia L. Craib, David J. Pasta, Stefanie J. Millar, Wayne J. Morgan, Michael W. Konstan, Tags: ORIGINAL ARTICLE: CYSTIC FIBROSIS Source Type: research
Inhalation delivery of complex drugs-the next steps.
Abstract
Oral inhalation offers the opportunity of targeting drugs locally to different regions of the respiratory tract or alternatively, using the high surface area of the alveoli for systemic delivery. Pulmozyme and the inhaled insulins (i.e. Exubera and Afrezza) are examples of the scope of pulmonary drug delivery of biopharmaceuticals-albeit with strikingly different commercial success. Particularly, the failure of Exubera and the subsequent overreactions (e.g. the unsubstantiated lung cancer fear), lastingly stunned the field of systemically inhaled protein and peptide drugs. Building on the lessons ...
Source: Current Opinion in Pharmacology - August 25, 2017 Category: Drugs & Pharmacology Authors: de Kruijf W, Ehrhardt C Tags: Curr Opin Pharmacol Source Type: research
Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention
ConclusionsAlthough individual patient results are impacted by the choice of reference equations, the study conclusions from this evaluation of a therapeutic intervention were minimally affected. GLI equations are recommended for future studies, but prior results based on other equations should be accepted as reliable. (Source: Pediatric Pulmonology)
Source: Pediatric Pulmonology - July 1, 2017 Category: Respiratory Medicine Authors: Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J. Pasta, Stefanie J. Millar, Wayne J. Morgan, Tags: ORIGINAL ARTICLE: CYSTIC FIBROSIS Source Type: research
Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial
A randomized controlled trial of adults with empyema recently demonstrated decreased length of stay in hospital in patients treated with intrapleurally administered dornase alfa and fibrinolytics compared to f... (Source: Trials)
Source: Trials - June 24, 2017 Category: General Medicine Authors: Michael H. Livingston, Sanjay Mahant, Felix Ratjen, Bairbre L. Connolly, Kevin Thorpe, Muhammad Mamdani, Ian Maclusky, Sophie Laberge, Lucy Giglia, J. Mark Walton, Connie L. Yang, Ashley Roberts, Anna C. Shawyer, Mary Brindle, Simon J. Parsons, Cristina A Source Type: research
